PubRank

Yasuhiro Asahina

Author PubWeight™ 35.89‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Risk factors for exceeding the Milan criteria after successful radiofrequency ablation in patients with early-stage hepatocellular carcinoma. Liver Transpl 2014 2.77
2 Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J Hepatol 2010 1.80
3 A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis. Hepatol Res 2010 1.58
4 Genome-wide association study confirming association of HLA-DP with protection against chronic hepatitis B and viral clearance in Japanese and Korean. PLoS One 2012 1.44
5 Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. Hepatology 2006 1.43
6 Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma. J Hepatol 2006 1.40
7 Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma. Oncology 2011 1.24
8 Influence of hepatitis B virus X and core promoter mutations on hepatocellular carcinoma among patients infected with subgenotype C2. J Clin Microbiol 2007 1.14
9 Hepatitis C virus NS4B protein targets STING and abrogates RIG-I-mediated type I interferon-dependent innate immunity. Hepatology 2013 1.03
10 Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma. Cancer 2013 1.00
11 Molecular tracing of Japan-indigenous hepatitis E viruses. J Gen Virol 2006 0.97
12 Non-invasive prediction of hepatocellular carcinoma development using serum fibrosis marker in chronic hepatitis C patients. J Gastroenterol 2013 0.96
13 No association for Chinese HBV-related hepatocellular carcinoma susceptibility SNP in other East Asian populations. BMC Med Genet 2012 0.94
14 A case of primary leiomyoma of the liver in a patient without evidence of immunosuppression. Hepatol Res 2002 0.92
15 Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin. Antivir Ther 2011 0.91
16 Mutations in the NS5B region of the hepatitis C virus genome correlate with clinical outcomes of interferon-alpha plus ribavirin combination therapy. J Gastroenterol Hepatol 2005 0.91
17 Hepatic steatosis in chronic hepatitis C is a significant risk factor for developing hepatocellular carcinoma independent of age, sex, obesity, fibrosis stage and response to interferon therapy. Hepatol Res 2010 0.91
18 The presence of steatosis and elevation of alanine aminotransferase levels are associated with fibrosis progression in chronic hepatitis C with non-response to interferon therapy. J Hepatol 2008 0.88
19 Expression of keratin 19 is related to high recurrence of hepatocellular carcinoma after radiofrequency ablation. Oncology 2011 0.87
20 Clinical characteristics of patients who developed hepatocellular carcinoma after hepatitis C virus eradication with interferon therapy: current status in Japan. Intern Med 2013 0.86
21 Hepatocellular carcinoma risk assessment using gadoxetic acid-enhanced hepatocyte phase magnetic resonance imaging. Hepatol Res 2014 0.84
22 Wnt5a signaling mediates biliary differentiation of fetal hepatic stem/progenitor cells in mice. Hepatology 2013 0.82
23 Prospective comparison of real-time tissue elastography and serum fibrosis markers for the estimation of liver fibrosis in chronic hepatitis C patients. Hepatol Res 2013 0.81
24 Polymerase domain B mutation is associated with hepatitis relapse during long-term lamivudine therapy for chronic hepatitis B. Intervirology 2005 0.80
25 Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis. Hepatol Res 2004 0.80
26 Model incorporating the ITPA genotype identifies patients at high risk of anemia and treatment failure with pegylated-interferon plus ribavirin therapy for chronic hepatitis C. J Med Virol 2013 0.80
27 Inhibition of hepatocellular carcinoma by PegIFNα-2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study. J Gastroenterol 2012 0.80
28 A comparison of the exponential decay slope between PEG-IFN alfa-2b/ribavirin and IFN alfa-2b/ribavirin combination therapy in patients with chronic hepatitis C genotype 1b infection and a high viral load. Intervirology 2004 0.80
29 Impaired brain activity in cirrhotic patients with minimal hepatic encephalopathy: Evaluation by near-infrared spectroscopy. Hepatol Res 2013 0.79
30 Changes in hepatitis C viral load during first 14 days can predict the undetectable time point of serum viral load by pegylated interferon and ribavirin therapy. Hepatol Res 2011 0.78
31 Impaired induction of interleukin 28B and expression of interferon λ 4 associated with nonresponse to interferon-based therapy in chronic hepatitis C. J Gastroenterol Hepatol 2015 0.78
32 Predictors of virological response to a combination therapy with pegylated interferon plus ribavirin including virus and host factors. Hepat Res Treat 2010 0.78
33 [Long time oral supplementation with branched-chain amino acids improves survival and decreases recurrences in patients with hepatocellular carcinoma]. Nihon Shokakibyo Gakkai Zasshi 2008 0.78
34 Repeated radiofrequency ablation for the distant recurrence in the liver in patients with chronic hepatitis C virus infection achieving long-term survival. Hepatol Res 2007 0.77
35 Reduced organic anion transporter expression is a risk factor for hepatocellular carcinoma in chronic hepatitis C patients: a propensity score matching study. Oncology 2014 0.77
36 Reproducibility and usability of chronic virus infection model using agent-based simulation; comparing with a mathematical model. Biosystems 2009 0.77
37 Primary hepatic neuroendocrine carcinoma with a cholangiocellular carcinoma component in one nodule. Clin J Gastroenterol 2014 0.77
38 Reply: To PMID 24734314. Liver Transpl 2014 0.75
39 Chronic Hepatitis E Infection in a Persistently Immunosuppressed Patient Unable to Be Eliminated after Ribavirin Therapy. Intern Med 2016 0.75
40 [A case of chronic hepatitis B managed with continued adefovir despite treatment-related Fanconi syndrome and osteomalacia]. Nihon Shokakibyo Gakkai Zasshi 2014 0.75
41 [Epithelioid hemangioendothelioma of the liver diagnosed by laparoscopy guided biopsy]. Nihon Shokakibyo Gakkai Zasshi 2008 0.75
42 [A case of systemic amyloidosis with cholangiectasis diagnosed by liver biopsy]. Nihon Shokakibyo Gakkai Zasshi 2013 0.75
43 [A case of advanced gastric cancer acquired long-term response two years or more by treatment with oral anticancer drug TS-1]. Gan To Kagaku Ryoho 2004 0.75
44 [Ulcerative colitis developed after acute exacerbation of chronic hepatitis B]. Nihon Naika Gakkai Zasshi 2002 0.75
45 [Present status of the treatment of chronic hepatitis C in Japan compared from Western countries]. Nihon Shokakibyo Gakkai Zasshi 2004 0.75
46 [Anti-HCV treatment for older patients]. Nihon Rinsho 2015 0.75
47 [Inhibitory effect of HCV-NS4B on IFN-λ induction]. Nihon Rinsho 2015 0.75
48 [Prognostic significance of fibrosis markers in hepatocellular carcinoma among patients with IFN-based therapy]. Nihon Rinsho 2015 0.75
49 [Chronic viral hepatitis: a discussion]. Nihon Naika Gakkai Zasshi 2008 0.75
50 Corrigendum: Amino Acid Polymorphisms in Hepatitis C Virus Core Affect Infectious Virus Production and Major Histocompatibility Complex Class I Molecule Expression. Sci Rep 2015 0.75
51 Serum KL-6 as a novel tumor marker for hepatocellular carcinoma in hepatitis C virus infected patients. Hepatol Res 2005 0.75